NNovartis Read More Merck’s $6.7B Terns Acquisition Positions It to Challenge a Blockbuster Novartis Cancer Drug2026-03-25 Merck is picking up a big new piece for its cancer drug pipeline with a $6.7 billion deal…
NNovartis Read More Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis’ Scemblix2026-03-25 Merck is looking to further solidify its oncology pipeline via a $6.7 billion cash acquisition of Terns Pharmaceuticals…